The 67th ASH Annual Meeting and Exposition brought over 30,000+ attendees, 5,000+ novel abstracts and 275+ exhibitors corporate supporters, academic leaders and patient-advocacy groups. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of haematology practice.
Discover the late-breaking abstracts
The six selected late-breaking abstracts showcase cutting-edge alternatives to conventional CAR-T therapy, refined strategies in immune disorders, landmark head-to-head trials in CLL/SLL, genomics and pragmatic perioperative care. We have broken down all six late-breaking abstracts, highlighting the key data, take-home messages and the insights that matter most for clinical practice.
Read the full article: ASH25: Discover the late-breaking abstracts
Top abstracts in non-malignant haematology
ASH25 spotlighted many pivotal trial results across non-malignant haematology including immune thrombocytopenia, bleeding disorders, iron deficiency, von Willebrand disease, cancer-associated hematologic complications and more. touchHAEMATOLOGY summarize some of the most important abstracts presented, and what this might mean for future clinical practice.
Read the full article: ASH25: Top abstracts in non-malignant haematology
Breakthroughs redefining transplantation and cell therapy
ASH25 delivered powerful advances across hematopoietic cell transplantation and cellular therapy, signaling a future that is safer, more precise and increasingly engineered. Dr Esra Gülderen highlights seven major abstracts from ASH25, highlighting their take-aways and considering their potential relevance for clinical practice.
Read the full article: Inside ASH25: Breakthroughs redefining transplantation and cell therapy
Latest in lymphoma
At ASH25, the lymphoma research landscape reflected both the ongoing challenges in frontline therapy for older and frail patients, and emerging opportunities with immunotherapeutic approaches. Investigators presented a series of trials exploring chemolight regimens, bispecific antibodies and novel single-agent strategies aimed at expanding options beyond conventional cytotoxic chemotherapy. Dr Tycel Phillips showcases five of the major abstracts from ASH25, highlighting their take-aways and considering their potential relevance for clinical practice.
Read the full article: ASH25: Latest in lymphoma
Late-breakers in multiple myeloma and CLL/SLL
ASH25 showcased transformative advances across multiple myeloma, chronic lymphocytic leukemia and small lymphocytic lymphoma, with bispecific antibodies, novel CAR T-cell strategies and next-generation targeted therapies redefining the treatment paradigm. Prof Meletios-Athanasios Dimopoulos highlights several of the most impactful clinical trials, underscoring a shifting therapeutic landscape in diseases long marked by incremental progress.
Read the full article: ASH25 round-up: Late-breakers in multiple myeloma and CLL/SLL
Cite: ASH25 highlights: Translating evidence into haematology practice. December 16th, 2025
Related content
- touchWRAPPED 2025: Your top reads, watches and listens in haematology
- CAR-T therapy: A new era for lymphoma
- #ASH24: Must-know updates in multiple myeloma
SIGN UP to touchHAEMATOLOGY!
Join our global community today for access to thousands of peer-reviewed articles, expert insights, and learn-on-the-go education across 150+ specialties, plus concise email updates and newsletters so you never miss out.
